rs369300885
Variant summary
Our verdict is Uncertain significance. Variant got 1 ACMG points: 2P and 1B. PM1BP4
The NM_000256.3(MYBPC3):c.682G>A(p.Asp228Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000057 in 1,613,096 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000256.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYBPC3 | NM_000256.3 | c.682G>A | p.Asp228Asn | missense_variant | 6/35 | ENST00000545968.6 | NP_000247.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYBPC3 | ENST00000545968.6 | c.682G>A | p.Asp228Asn | missense_variant | 6/35 | 5 | NM_000256.3 | ENSP00000442795.1 | ||
MYBPC3 | ENST00000399249.6 | c.682G>A | p.Asp228Asn | missense_variant | 6/34 | 5 | ENSP00000382193.2 | |||
MYBPC3 | ENST00000544791.1 | n.682G>A | non_coding_transcript_exon_variant | 6/27 | 5 | ENSP00000444259.1 |
Frequencies
GnomAD3 genomes AF: 0.0000395 AC: 6AN: 152076Hom.: 0 Cov.: 29
GnomAD3 exomes AF: 0.0000810 AC: 20AN: 247026Hom.: 0 AF XY: 0.0000894 AC XY: 12AN XY: 134234
GnomAD4 exome AF: 0.0000589 AC: 86AN: 1460902Hom.: 1 Cov.: 31 AF XY: 0.0000647 AC XY: 47AN XY: 726664
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152194Hom.: 0 Cov.: 29 AF XY: 0.0000672 AC XY: 5AN XY: 74410
ClinVar
Submissions by phenotype
Cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Mar 23, 2023 | This missense variant replaces aspartic acid with asparagine at codon 228 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). An experimental study has shown that this variant weakens the interaction with myosin S2 domain (PMID: 18926831). This variant has been reported in two individuals affected with hypertrophic cardiomyopathy (PMID: 11748309, 26914223). This variant has been identified in 22/278398 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Oct 19, 2020 | - - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Apr 24, 2023 | BP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 01, 2024 | In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 24055113, 18374358, 26914223, 11748309, 23299917, 15114369, 25637381, 21415409, 18926831) - |
Hypertrophic cardiomyopathy Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2023 | This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 228 of the MYBPC3 protein (p.Asp228Asn). This variant is present in population databases (rs369300885, gnomAD 0.01%). This missense change has been observed in individuals with HCM (PMID: 11748309, 26914223). This variant is also known as g.5166G>A (p.D228N). ClinVar contains an entry for this variant (Variation ID: 161304). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects MYBPC3 function (PMID: 18926831). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Aug 31, 2024 | This missense variant replaces aspartic acid with asparagine at codon 228 of the MYBPC3 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). An experimental study has shown that this variant weakens the interaction with myosin S2 domain (PMID: 18926831). This variant has been reported in two individuals affected with hypertrophic cardiomyopathy (PMID: 11748309, 26914223). This variant has been identified in 22/278398 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Left ventricular noncompaction 10 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jan 01, 2019 | - - |
Hypertrophic cardiomyopathy 4 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
Primary familial hypertrophic cardiomyopathy Uncertain:1
Uncertain significance, no assertion criteria provided | research | CSER _CC_NCGL, University of Washington | Jun 01, 2014 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 10, 2023 | The p.D228N variant (also known as c.682G>A), located in coding exon 6 of the MYBPC3 gene, results from a G to A substitution at nucleotide position 682. The aspartic acid at codon 228 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been reported in individuals with hypertrophic cardiomyopathy (HCM) (Andersen PS et al. J Med Genet, 2001 Dec;38:E43; Murphy SL et al. J Cardiovasc Transl Res, 2016 Apr;9:153-61). This variant has also been seen in an exome cohort, but cardiovascular history was not provided (Andreasen C et al. Eur J Hum Genet, 2013 Sep;21:918-28). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
MYBPC3-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 23, 2024 | The MYBPC3 c.682G>A variant is predicted to result in the amino acid substitution p.Asp228Asn. This variant was reported in at least two individuals with hypertrophic cardiomyopathy (Andersen et al. 2001. PubMed ID: 11748309; Andersen et al. 2004. PubMed ID: 15114369; Jensen et al. 2013. PubMed ID: 23197161; Table S1, Murphy et al. 2016. PubMed ID: 26914223). Functional studies indicate this variant may disrupt myosin binding affinity (Ababou et al. 2008. PubMed ID: 18926831). This variant is reported in 0.011% of alleles in individuals of Latino descent in gnomAD and is interpreted as uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/161304/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at